Global Individual Case Safety Reports (ICSR)

Reporting and Submissions

ICSR Reporting

Ensuring patient safety is the most important component of a pharmacovigilance (PV) system. Therefore, all pharmaceutical and biotechnology companies are required to identify, collect, and process Individual Case Safety Reports (ICSRs) in a systematic and robust manner, and report to regulatory authorities in accordance with strict requirements and timelines.

ProPharma recognizes the critical nature of accurate and on-time submissions to regulatory authorities, Institutional Review Boards (IRBs), Ethics Committees (ECs), and investigator sites.

We perform ICSR submissions including MedWatch, CIOMS I, E2B(R2), and E2B(R3) reports for various product types including approved and non-approved drugs, biologics, devices, vaccines, dietary supplements, cosmetics, homeopathic products, and natural health products.

Business professionals smiling at a desk reviewing data
Hands gesturing over data and charts

ProPharma's ICSR Workflow

ICSRs are exchanged with clients and Sponsors for review and comment before the final submission, if requested. Clients and Sponsors also maintain oversight of case processing and reporting activities ahead of submission via Case Explorer, a read-only application that allows for real-time database queries and review of information within individual cases.

Clients and Sponsors who wish to maintain oversight of case processing within the safety database itself may also do so via read-only access as part of individual user implementation and security procedures.

ICSR Submissions & Reporting

Ensure compliance and patient safety with ProPharma's expert ICSR processing and reporting. Our comprehensive pharmacovigilance services streamline your safety data management, ensuring accuracy and efficiency.

ICSR Compliance

QPPV office icon

Monthly Compliance Metrics

Each month, compliance metrics are generated from submission records in the safety database for all pharmacovigilance and clinical safety programs and shared with all...

Read More

Monthly Compliance Metrics

Each month, compliance metrics are generated from submission records in the safety database for all pharmacovigilance and clinical safety programs and shared with all interested clients.

Read Less
Compliance

+99% Compliance Submission Rate

ProPharma is proud to post a greater than 99% compliance rate, successfully submitting over 2,000 ICSRs per month to regulatory authorities and business partners on...

Read More

+99% Compliance Submission Rate

ProPharma is proud to post a greater than 99% compliance rate, successfully submitting over 2,000 ICSRs per month to regulatory authorities and business partners on behalf of post-marketing pharmacovigilance clients and clinical safety Sponsors.

Read Less

Frequently Asked Questions about ICSRs

Medical Information icon

What is an Individual Case Safety Report (ICSR)?

What is an Individual Case Safety Report (ICSR)?

Expert Witness icon

What are the FDA requirements for an ICSR?

What are the FDA requirements for an ICSR?

Product compliant intake icon

What are the MHRA/EMA requirements for an ICSR?

What are the MHRA/EMA requirements for an ICSR?

What is an Individual Case Safety Report (ICSR)?

An Individual Case Safety Report (ICSR) is a document that captures information needed to report one or more suspected adverse reactions to a medical product that occur in a single patient at a specific point in time. ICSRs are used to support the monitoring and evaluation of the safety and effectiveness of medical products, such as drugs, biologics, vaccines, devices, and tobacco products. ICSRs are also used to identify potential signals of new or emerging safety issues, or changes in the known safety profile of a product.

health-care-worker-wearing-headset-working-on-laptop-ss-1829353274-650x425

What are the FDA requirements for an ICSR?

The FDA requirements for an ICSR are as follows:

  • An ICSR should include the following information:
    • Patient information, such as patient identification code and age at the time of adverse drug experience.
    • Adverse event information, such as outcome attributed to adverse drug event.
    • Suspect medical product information, such as name. 
    • Initial reporter information, such as name, address, and telephone number.
    • Applicant information, as defined in section 760 (b) of the FD&C Act.
  • Submitted electronically using the ISO ICSR/ ICH E2B (R2/R3) format and related ISO standard terminology for pharmaceutical form and route of administration.
  • Clinical trial Suspected Unexpected Serious Adverse Reactions (SUSARs) are submitted within 7 days for fatal/life threatening reports and 15 days for all other serious reports.
  • Post marketed serious ICRS are submitted within 15 days and within 90 days for non-serious EU ICSRs, according to the regulatory reporting guidelines.
  • Submitted to the FDA Adverse Event Reporting System (FAERS) or to the appropriate FDA center, depending on the product type and submission method.
  • An ICSR should follow the guidance documents, implementation guides, specifications, schema files, and validation procedures published by the FDA for electronic submission of ICSRs.
Business professionals discussing data around a conference table

What are the MHRA/EMA requirements for an ICSR?

The EMA requirements for an ICSR are as follows:

  • Per the GVP module VI requirements this must include an identifiable reporter, an identifiable patient, adverse reaction information, and a suspect medicinal product.
  • Should be submitted electronically using the ISO ICSR/ICH E2B (R3) format and related ISO standard terminology for pharmaceutical form and route of administration.
  • Clinical trial Suspected Unexpected Serious Adverse Reactions (SUSARs) are submitted within 7 days for fatal/life threatening reports and 15 days for all other serious reports.
  • Post marketed serious ICRS are submitted within 15 days and within 90 days for non-serious ICSRs, according to the regulatory reporting guidelines.
  • Submitted to the applicable regulatory authority (e.g. EudraVigilance database or MHRA ICSR portal)where the suspected adverse reaction occurred, depending on the marketing authorization procedure and the origin of the ICSR.
Business and healthcare professionals smiling around charts

News & Insights

Medical Information in the Netherlands: Safeguarding Compliance and Patient Confidence

October 2, 2025

Medical Information in the Netherlands: Safeguarding Compliance and Patient Conf...

Discover how ProPharma's medical information services in the Netherlands ensure patient safety, regulatory compliance, and data privacy with expert support.

Tips for Preparing Successful FDA 510(k) Submissions

September 30, 2025

Tips for Preparing Successful FDA 510(k) Submissions

Discover essential tips for preparing a successful FDA 510(k) submission. Learn common pitfalls to avoid, align with FDA expectations, and streamline your path to clearance.

FDA’s Crackdown on Drug Advertising: Key Lessons from 60 Compliance Letters in 2025

September 26, 2025

FDA’s Crackdown on Drug Advertising: Key Lessons from 60 Compliance Letters in 2...

Insights from FDA’s latest round of compliance letters which indicates a major shift in ad promo oversight revealing new compliance risks for Sponsors.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Appoints Brian Tuttle as Chief Financial Officer

October 21, 2024

ProPharma Appoints Brian Tuttle as Chief Financial Officer

ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study Critical Database Lock Milestone Achieved Through Rapid FSP Support for BioXcel Therapeutics, Inc. - ProPharma

October 6, 2025

Critical Database Lock Milestone Achieved Through Rapid FSP Support for BioXcel ...

When BioXcel Therapeutics’ pivotal Phase 3 study faced a critical slowdown, timelines and regulatory goals were at risk. With their primary CRO unable to meet growing demands, ProPharma stepped in —...

Whitepapers Your Complete FDA 510(k) Premarket Notification Checklist

September 30, 2025

Your Complete FDA 510(k) Premarket Notification Checklist

Step-by-step guide to navigating the FDA 510(k) submission process with confidence Submitting a 510(k) premarket notification is a critical milestone for medical device manufacturers seeking U.S....

Infographic Unannounced FDA Inspections Without Borders - ProPharma

September 19, 2025

Unannounced FDA Inspections Without Borders

Unannounced FDA inspections are no longer limited to the U.S. — they’re expanding globally. Starting in 2025, foreign sites will face the same surprise visits and public scrutiny as U.S. facilities,...

Navigating the New EU HTA Regulation as an MAH: Strategic Insights for Successful JCA Submissions

November 18, 2025

Navigating the New EU HTA Regulation as an MAH: Strategic Insights for Successful JCA Submissions

Explore how the new EU HTA Regulation (EU HTAR) is transforming market access across Europe. Join our expert to learn practical strategies for successful Joint Clinical Assessment (JCA) submissions,...

Tips for Successful MAA Submissions in Europe

November 11, 2025

Tips for Successful MAA Submissions in Europe

Navigate the complexities of EU marketing authorization to explore tips for successful Marketing Authorization Application (MAA) submissions in Europe to ensure proven strategies, reduced delays, and...

AI in Medical Information: Who Holds the Responsibility?

October 16, 2025

AI in Medical Information: Who Holds the Responsibility?

In Medical Information (MI) and beyond, key questions arise: Who ensures accuracy, compliance, and ethical use — individual contributors, leadership, pharma clients, or technology providers? And what...

News & Insights

Medical Information in the Netherlands: Safeguarding Compliance and Patient Confidence

October 2, 2025

Medical Information in the Netherlands: Safeguarding Compliance and Patient Conf...

Discover how ProPharma's medical information services in the Netherlands ensure patient safety, regulatory compliance, and data privacy with expert support.

Tips for Preparing Successful FDA 510(k) Submissions

September 30, 2025

Tips for Preparing Successful FDA 510(k) Submissions

Discover essential tips for preparing a successful FDA 510(k) submission. Learn common pitfalls to avoid, align with FDA expectations, and streamline your path to clearance.

FDA’s Crackdown on Drug Advertising: Key Lessons from 60 Compliance Letters in 2025

September 26, 2025

FDA’s Crackdown on Drug Advertising: Key Lessons from 60 Compliance Letters in 2...

Insights from FDA’s latest round of compliance letters which indicates a major shift in ad promo oversight revealing new compliance risks for Sponsors.

Previous Post Arrow Next Post Arrow
ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Appoints Brian Tuttle as Chief Financial Officer

October 21, 2024

ProPharma Appoints Brian Tuttle as Chief Financial Officer

ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study Critical Database Lock Milestone Achieved Through Rapid FSP Support for BioXcel Therapeutics, Inc. - ProPharma

October 6, 2025

Critical Database Lock Milestone Achieved Through Rapid FSP Support for BioXcel ...

When BioXcel Therapeutics’ pivotal Phase 3 study faced a critical slowdown, timelines and regulatory goals were at risk. With their primary CRO unable to meet growing demands, ProPharma stepped in —...

Whitepapers Your Complete FDA 510(k) Premarket Notification Checklist

September 30, 2025

Your Complete FDA 510(k) Premarket Notification Checklist

Step-by-step guide to navigating the FDA 510(k) submission process with confidence Submitting a 510(k) premarket notification is a critical milestone for medical device manufacturers seeking U.S....

Infographic Unannounced FDA Inspections Without Borders - ProPharma

September 19, 2025

Unannounced FDA Inspections Without Borders

Unannounced FDA inspections are no longer limited to the U.S. — they’re expanding globally. Starting in 2025, foreign sites will face the same surprise visits and public scrutiny as U.S. facilities,...

Previous Resource Arrow Next Resource Arrow
Navigating the New EU HTA Regulation as an MAH: Strategic Insights for Successful JCA Submissions

November 18, 2025

Navigating the New EU HTA Regulation as an MAH: Strategic Insights for Successful JCA Submissions

Explore how the new EU HTA Regulation (EU HTAR) is transforming market access across Europe. Join our expert to learn practical strategies for successful Joint Clinical Assessment (JCA) submissions,...

Tips for Successful MAA Submissions in Europe

November 11, 2025

Tips for Successful MAA Submissions in Europe

Navigate the complexities of EU marketing authorization to explore tips for successful Marketing Authorization Application (MAA) submissions in Europe to ensure proven strategies, reduced delays, and...

AI in Medical Information: Who Holds the Responsibility?

October 16, 2025

AI in Medical Information: Who Holds the Responsibility?

In Medical Information (MI) and beyond, key questions arise: Who ensures accuracy, compliance, and ethical use — individual contributors, leadership, pharma clients, or technology providers? And what...

Previous Webinar Arrow Next Webinar Arrow